pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
CRO/CDMO · news · pharmadog
← back to CRO/CDMO
News · CRO/CDMO
56
stories
20h
WuXi Bio to offload chromatography unit; Cabaletta names another CDMO partner
endpoints
1d
7 biopharma M&A deals where layoffs followed
biospace
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
2d
Developing a Global Clinical Trial Strategy for Emerging Biotechs
fiercebiotech
2d
Rebounding biotech funds expected to spur CDMO growth within year
biospace
4d
Baylor Genetics hit by cybersecurity attack targeting patient, staff information
fiercebiotech
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
8d
July's biopharma layoffs affect 466 employees, a 94% year-over-year drop
biospace
8d
AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: report
fiercebiotech
9d
CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques
fiercebiotech
9d
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
biospace
10d
IRBs have a problem. Can North Star’s nonprofit model save it?
stat
10d
Judge blocks enforcement of WuXi AppTec's designation as Chinese military company
endpoints
11d
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
13d
2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees
biospace
14d
Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy
endpoints
15d
CROs vs. biotechs: Finding the right fit
biospace
15d
In a first, WuXi AppTec surpasses Lonza’s six-month revenue
endpoints
15d
Over 1/3 stay in biopharma jobs for health insurance, poll finds
biospace
16d
Icon inks Anthropic partnership to deploy Claude into clinical trials
fiercebiotech
17d
Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
fiercebiotech
17d
KKR inks $5.7B deal to take medtech manufacturing giant Integer private
fiercebiotech
18d
Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity
biospace
18d
Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out
biospace
20d
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
20d
Resilience and Lilly invest $750M to boost Cincinnati drug production
biopharma dive
21d
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
22d
Not-so-special delivery: When biopharmas fumble layoff news
biospace
← prev
page 1 of 2
next →
